A Phase 4 Study of Venetoclax in Combination With Azacitidine in Newly Diagnosed Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy in China
Latest Information Update: 10 Dec 2024
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AbbVie
- 06 Dec 2024 Planned End Date changed from 28 Jul 2024 to 1 Apr 2025.
- 06 Dec 2024 Planned primary completion date changed from 28 Jul 2024 to 1 Apr 2025.
- 27 Jun 2023 Planned End Date changed from 26 Jul 2024 to 28 Jul 2024.